The Ministry of Health of Russia issued a permit to LLC Rionis to conduct clinical studies of the first phase of the drug Prottremin (Diol) for the treatment of Parkinson’s disease.
Rionis is allowed to begin an assessment of the safety, tolerability and pharmacokinetic parameters of the drug on healthy volunteers.
This study is planned for nine months on the basis of the Siberian State Medical University.
Protremin was patented in Russia and abroad as an innovative drug with a pronounced dopamine-positive effect, eliminating parkinsonism symptoms at the level of the “gold standard of therapy” – Levodopa.
However, Protremin is not a precursor of dopamine, it does not inhibit the enzymes of it degradation, does not bind to the receptors of neurotransmitters.
The results of laboratory studies have shown that Protremin protects the brain from damage by neurotoxins – mitochondrial poisons in vivo and restores the affected neurons in an in vitro culture.